

CORRESPONDENCE

Lactobacillus for Gastroenteritis in Children

TO THE EDITOR: Schnadower et al. (Nov. 22 issue)¹ report that preschool children with acute gastroenteritis who received a 5-day course of *Lactobacillus rhamnosus* GG did not have better outcomes than those who received placebo. The authors did not highlight a crucial limitation of the trial: stool samples were obtained from 78.4% of the participants, with 45.6% of these samples positive for viruses. A therapeutic benefit of probiotics has been documented mostly in acute gastroenteritis of a viral origin.^{2,3}

Furthermore, probiotics are more effective when administered early in the course of diarrhea rather than later,^{2,3} whereas in most participants in this trial, therapy was initiated on the third or fourth day of diarrhea. Finally, some of the participants received antibiotics, although many strains of lactobacilli are susceptible to antimicrobial agents.⁴ Moreover, after antibiotic therapy, probiotics induced a markedly delayed and incomplete reconstitution of the intestinal mucosal microbiome.⁵

Zvi Weizman, M.D.

Ben-Gurion University of the Negev
Beer-Sheva, Israel
wzvi@bgu.ac.il

No potential conflict of interest relevant to this letter was reported.

1. Schnadower D, Tarr PI, Casper TC, et al. *Lactobacillus rhamnosus* GG versus placebo for acute gastroenteritis in children. *N Engl J Med* 2018;379:2002-14.
2. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. *Pediatrics* 2010;126:1217-31.
3. Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. *J Pediatr Gastroenterol Nutr* 2008;46:Suppl 2: S81-S122.
4. Georgieva R, Yocheva L, Tserovska L, et al. Antimicrobial activity and antibiotic susceptibility of *Lactobacillus* and *Bifidobacterium* spp. intended for use as starter and probiotic cultures. *Biotechnol Biotechnol Equip* 2015;29:84-91.
5. Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. *Cell* 2018;174(6):1406-1423.e16. DOI: 10.1056/NEJMc1900909

TO THE EDITOR: Schnadower et al. found that *L. rhamnosus* GG was ineffective in acute gastroenteritis in children. They provided several expla-

nations for their negative results, which contrasted with available data supporting the use of *L. rhamnosus* GG in children.^{1,2}

Unfortunately, the authors did not report important weaknesses of their trial. For example, data show that probiotics should ideally be initiated early in the course of gastroenteritis.^{3,4} In this trial, the median duration of diarrhea before treatment was 53.2 hours (range, 29.0 to 81.3). This delay seems too long for a disease that typically lasts less than 7 days. With such a delay in the beginning of treatment, it is hard to show a difference in the duration of diarrhea. In addition, with the use of a primary outcome based on a score of 9 or higher on the Vesikari scale (scores range from 0 to 20, with higher scores indicating more severe disease), which was determined at any time point during the 14-day follow-up period after enrollment, it is hard to determine the effect of *L. rhamnosus* GG on the duration and severity of gastroenteritis. Previous studies used the total duration of diarrhea (in hours) as the primary outcome. To provide solid guidance on the use of probiotics in acute gastroenteritis, it would be important to perform a large trial to confirm previous data from smaller studies. However, to confirm the results of previous trials, it would be better to adopt the same trial design and clinical outcomes. Otherwise, there is a risk that “bigger” will not become “better.”

Roberto Berni Canani, M.D., Ph.D.

University of Naples Federico II
Naples, Italy
berni@unina.it

Dr. Berni Canani reports receiving a research grant and speaking fees from Sofar, a research grant from Humana, a research grant and speaking fees from Mead Johnson Nutrition, and a research grant and speaking fees from Sanofi as part of publicly funded research. No other potential conflict of interest relevant to this letter was reported.

1. Szajewska H, Guarino A, Hojsak I, et al. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. *J Pediatr Gastroenterol Nutr* 2014;58:531-9.
2. Szajewska H, Skórka A, Ruszczyński M, Gieruszczak-Bialek D. Meta-analysis: *Lactobacillus* GG for treating acute gastroenteritis in children — updated analysis of randomised controlled trials. *Aliment Pharmacol Ther* 2013;38:467-76.

3. Guarino A, Lo Vecchio A, Dias JA, et al. Universal recommendations for the management of acute diarrhea in nonmalnourished children. *J Pediatr Gastroenterol Nutr* 2018;67:586-93.
4. Hojsak I, Fabiano V, Pop TL, et al. Guidance on the use of probiotics in clinical practice in children with selected clinical conditions and in specific vulnerable groups. *Acta Paediatr* 2018; 107:927-37.

DOI: 10.1056/NEJMc1900909

TO THE EDITOR: A Cochrane systematic review¹ concluded that the use of specific probiotics along with rehydration therapy has beneficial effects in reducing the duration and stool frequency of acute infectious diarrhea. Cochrane experts acknowledged variability among studies and stated that research is needed to guide the use of particular probiotic regimens in specific patient groups.

The results of the trial by Schnadower et al. and those of the trial by Freedman et al., which were published in the same issue of the *Journal*,² should be interpreted with caution because of the late use of probiotic therapy and the unverified viability of strains in liquid suspension in both trials. Most children had mild gastroenteritis and were recruited after they had had diarrhea for 2 days. Guidelines recommend probiotic use within the first 24 to 48 hours after symptom onset in order to be effective.³ Infectious gastroenteritis in Western societies is typically mild and self-limiting, and the use of probiotics may not be critical.⁴ This is not the same in less developed areas. It would be advisable to perform a subanalysis focusing only on severe cases of diarrhea treated with reliable probiotic dosing within the first 48 hours after the onset of symptoms in order to properly assess the effectiveness of the intervention.

Guillermo Alvarez-Calatayud, M.D., Ph.D.

Gregorio Marañón Hospital
Madrid, Spain
galvarezcalatayud@gmail.com

Teresa Requena, Ph.D.

Abelardo Margolles, Ph.D.

Spanish National Research Council
Madrid, Spain

No potential conflict of interest relevant to this letter was reported.

1. Allen SJ, Martínez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. *Cochrane Database Syst Rev* 2010;11:CD003048.
2. Freedman SB, Williamson-Urquhart S, Farion KJ, et al. Multicenter trial of a combination probiotic for children with gastroenteritis. *N Engl J Med* 2018;379:2015-26.
3. Szajewska H, Guarino A, Hojsak I, et al. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. *J Pediatr Gastroenterol Nutr* 2014;58:531-9.
4. Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R,

Szajewska H. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. *J Pediatr Gastroenterol Nutr* 2014;59:132-52.
DOI: 10.1056/NEJMc1900909

DR. SCHNADOWER AND COLLEAGUES REPLY: All three letters express the oft-stated belief that the sooner probiotics are initiated in acute gastroenteritis, the greater the effect. However, the references cited in these letters do not provide specific data supporting this contention. The only relevant data we found for the use of *L. rhamnosus* GG for the treatment of acute gastroenteritis in a population similar to ours showed a nonsignificant benefit in patients with symptoms lasting more than 48 hours.¹ We stratified participants according to the duration of symptoms (<48 hours vs. ≥48 hours) and identified no significant differences according to the time of initiation of the probiotic (Fig. S1 in the Supplementary Appendix, available with the full text of our article at NEJM.org).

Weizman contends that the inclusion of participants who were receiving antibiotics was a weakness of the trial and that viruses were detected in stool samples obtained from fewer than half the participants. We chose to include participants who were receiving antibiotics because probiotics are often used (with limited evidence) to prevent antibiotic-associated diarrhea, treat it, or both. No bona fide enteric pathogens are detected in stool samples obtained from many patients with acute gastroenteritis in North America, even with the use of multiplex polymerase-chain-reaction assays containing more viral targets than the one we used and in populations with sparse rotavirus vaccine penetration.² Figure S1 in the Supplementary Appendix of our article addressed antibiotic use and a viral cause of diarrhea as possible determinants of the efficacy of probiotics, and we found no such influences.

Berni Canani questions the use of a total score of 9 or higher on the modified Vesikari scale as our primary outcome instead of the duration of diarrhea. We prefer the Vesikari scale score because it includes multiple aspects of gastroenteritis severity and we think it better reflects the burden of the disease in our population.³ However, we also addressed the duration of diarrhea as a secondary outcome, and we found no difference between the treatment group and the placebo group (Table 3 of our article).

Alvarez-Calatayud et al. express concern that viability was lost because the probiotics were suspended in a liquid form. Because most young participants cannot swallow capsules, we sprinkled the contents of each capsule in 20 ml of liquid at the time of administration; this common practice was recommended by the manufacturer. We independently tested all batches of *L. rhamnosus* GG at regular intervals to ensure purity and viability. Alvarez-Calatayud et al. state that probiotics may be less effective in Western societies, where gastroenteritis is usually mild; this statement contradicts the findings reported in one of their references.⁴ We agree that the burden of gastroenteritis is greater in less developed areas. However, we will not know whether *L. rhamnosus* GG or probiotics improve patients' outcomes in such environments until rigorous studies are conducted in those settings.

David Schnadower, M.D., M.P.H.

Cincinnati Children's Hospital Medical Center
Cincinnati, OH
david.schnadower@cchmc.org

Phillip I. Tarr, M.D.

Washington University School of Medicine in St. Louis
St. Louis, MO

Stephen B. Freedman, M.D.C.M.

University of Calgary
Calgary, AB, Canada

Since publication of their article, the authors report no further potential conflict of interest.

1. Nixon AF, Cunningham SJ, Cohen HW, Crain EF. The effect of *Lactobacillus* GG on acute diarrheal illness in the pediatric emergency department. *Pediatr Emerg Care* 2012;28:1048-51.
2. Xie J, Nettel-Aguirre A, Lee BE, et al. Relationship between enteric pathogens and acute gastroenteritis disease severity: a prospective cohort study. *Clin Microbiol Infect* 2019;25:454-61.
3. Schnadower D, Tarr PI, Gorelick MH, et al. Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments. *J Pediatr Gastroenterol Nutr* 2013;57:514-9.
4. Szajewska H, Guarino A, Hojsak I, et al. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. *J Pediatr Gastroenterol Nutr* 2014;58:531-9.

DOI: 10.1056/NEJMc1900909

DR. FREEDMAN AND COLLEAGUES REPLY: Alvarez-Calatayud et al. cite a review¹ that is prone to the same limitations as all systematic reviews,² and the outcomes of ensuing large, randomized, controlled trials are poorly predicted by such reviews.³ Studies reporting positive results are more often published than those that report negative results⁴; this leads subsequent systematic reviews² to overestimate the treatment effect

size. Although we limited eligibility in our trial to participants who had had symptoms for less than 72 hours, only 17% of our trial population presented within 24 hours after symptom onset, and 53% presented within 48 hours after symptom onset. In these subgroups, the respective odds ratios for the development of moderate-to-severe disease among participants who received probiotics were 1.05 (95% confidence interval [CI], 0.47 to 2.33) and 1.20 (95% CI, 0.79 to 1.83).

Evidence of the viability of the probiotic strain in liquid preparations has been published⁵ and is available from the manufacturer, which also confirmed colony-forming unit counts for all trial batches at the end of the shelf life. The disease severity effect was assessed by evaluating the interaction between the treatment and the baseline Vesikari scale score, and it was not significant ($P=0.86$). We performed subgroup analyses involving children who presented less than 48 hours after symptom onset with varying degrees of baseline severity. An analysis involving 134 children who had a baseline Vesikari scale score of 11 or higher yielded an odds ratio for moderate-to-severe gastroenteritis of 1.26 (95% CI, 0.61 to 2.61), whereas the analysis involving 256 children with a Vesikari scale score of 9 or less yielded an odds ratio of 0.89 (95% CI, 0.48 to 1.66).

Stephen B. Freedman, M.D.C.M.

University of Calgary
Calgary, AB, Canada
stephen.freedman@ahs.ca

Philip M. Sherman, M.D.

Suzanne Schuh, M.D.

University of Toronto
Toronto, ON, Canada

Since publication of their article, the authors report no further potential conflict of interest.

1. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. *Cochrane Database Syst Rev* 2010;11:CD003048.
2. Sivakumar H, Peyton PJ. Poor agreement in significant findings between meta-analyses and subsequent large randomized trials in perioperative medicine. *Br J Anaesth* 2016;117:431-41.
3. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. *N Engl J Med* 1997;337:536-42.
4. Dwan K, Gamble C, Williamson PR, Kirkham JJ. Systematic review of the empirical evidence of study publication bias and outcome reporting bias — an updated review. *PLoS ONE* 2013;8(7):e66844.
5. Champagne CP, Raymond Y, Gagnon R. Viability of *Lactobacillus rhamnosus* R0011 in an apple-based fruit juice under simulated storage conditions at the consumer level. *J Food Sci* 2008;73:M221-M226.

DOI: 10.1056/NEJMc1900909

Correspondence Copyright © 2019 Massachusetts Medical Society.